复锐医疗科技(01696)发布公告，公司于2026年1月与星迈泰科医疗科技(北京)有限公司签订合作意向 书，就于中国的本土化潜在合作构建战略合作框架。根据合作意向书，潜在合作拟于中国(集团核心战 略市场之一)建立本土化生产，聚焦于能量源医美设备布局。这是公司践行战略的重要举措，即通过有 效缩短供应链并提升本地市场响应效率来深化以客户为中心的核心战略。此举不仅旨在满足国内需求， 还将为亚太战略枢纽打造区域基石，以满足整个地区对规模化量产、高效物流体系和先进技术日益增长 的需求。 ...

复锐医疗科技(01696)发布公告，公司于2026年1月与星迈泰科医疗科技(北京)有限公司签订合作意向 书，就于中国的本土化潜在合作构建战略合作框架。根据合作意向书，潜在合作拟于中国(集团核心战 略市场之一)建立本土化生产，聚焦于能量源医美设备布局。这是公司践行战略的重要举措，即通过有 效缩短供应链并提升本地市场响应效率来深化以客户为中心的核心战略。此举不仅旨在满足国内需求， 还将为亚太战略枢纽打造区域基石，以满足整个地区对规模化量产、高效物流体系和先进技术日益增长 的需求。 ...

Core Viewpoint - The company, Furuya Medical Technology (01696.HK), has signed a letter of intent with Xingmaitike Medical Technology (Beijing) Co., Ltd. to establish a strategic cooperation framework for localized production in China, focusing on energy source medical aesthetic equipment [1] Group 1: Strategic Initiatives - The potential collaboration aims to establish localized production in China, which is one of the company's core strategic markets [1] - This initiative is part of the company's strategy to shorten the supply chain and enhance local market responsiveness, emphasizing a customer-centric approach [1] Group 2: Regional Impact - The move is intended to meet domestic demand and create a regional foundation for the Asia-Pacific strategic hub [1] - The collaboration addresses the growing demand in the region for scalable mass production, efficient logistics systems, and advanced technology [1]

（ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* – 1 – 由於潛在合作取決於是否將訂立任何最終協議，且未必會進行，故本公司股東及 潛在投資者於買賣本公司股份時務請審慎行事。 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 Lior Moshe DAYAN 中國本土化潛在合作 本公告由復銳醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 發佈。 本公司欣然宣佈，本公司於二零二六年一月與星邁泰科醫療科技（北京）有限公司 （「星邁泰科醫療」）簽訂合作意向書（「合作意向書」），就於中華人民共和國（「中 國」）的本土化潛在合作（「潛在合作」）構建戰略合作框架。 根據合作意向書，潛在合作擬於中國（本集團核心戰略市場之一）建立本土化生 產，聚焦於能量源醫美設備佈 ...

Group 1 - The core viewpoint of the report highlights the growth potential of Ruiri Medical Technology, which is expanding its business from energy-based medical aesthetics to a diversified beauty and health ecosystem through acquisitions and market expansion [1] - The global market for energy-based medical devices reached $5.7 billion in 2022, with a projected CAGR of 13.8% from 2023 to 2030, indicating strong growth prospects [1] - North America accounted for 35.4% of the global market in 2022, while the Asia-Pacific region is expected to have a higher growth rate of 15.6% from 2023 to 2030 [1] Group 2 - The company is focusing on product development, channel expansion, and research and development to achieve steady global growth [1] - The product range includes various energy sources such as lasers, intense pulsed light, radiofrequency, ultrasound, plasma, and shockwave, catering to comprehensive beauty needs [1] - The company has established a sales network covering over 110 countries and regions by combining distribution and direct sales strategies, aiming for significant optimization of product pricing and overall performance [1] Group 3 - Long-acting botulinum toxin is expected to gain rapid market acceptance due to its advantages, including a median duration of 6 months and a maximum of 9 months, addressing consumer concerns about frequent injections [2] - The industry is anticipated to accelerate its development phase due to improved policies, consumer education, product technology iterations, and channel penetration [2] - Revenue projections for the company are $395 million, $468 million, and $530 million for 2025, 2026, and 2027, respectively, with corresponding net profits of $31 million, $45 million, and $57 million [2]